TransMedics Group Inc (TMDX)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
The days of sales outstanding (DSO) for TransMedics Group Inc, based on the provided data, is not available for all the reporting periods up to December 31, 2024. This ratio typically measures the average number of days a company takes to collect revenue after a sale has been made. Unfortunately, without specific values for DSO, it is challenging to assess the efficiency of TransMedics' accounts receivable management over time. Tracking DSO over different periods could provide insights into the company's ability to collect outstanding payments from customers promptly. A decreasing trend in DSO would indicate improvements in cash flow management, while an increasing trend might raise concerns about potential liquidity issues. It would be beneficial to have more detailed information to conduct a comprehensive analysis of TransMedics' DSO and its implications on the company's financial performance.
Peer comparison
Dec 31, 2024